Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $6.01 and traded as high as $6.81. Aldeyra Therapeutics shares last traded at $6.68, with a volume of 797,432 shares.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Aldeyra Therapeutics in a research note on Monday, March 3rd.
Check Out Our Latest Analysis on ALDX
Aldeyra Therapeutics Stock Up 6.5 %
The firm has a 50 day moving average of $6.10 and a two-hundred day moving average of $5.52. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80.
Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last issued its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.30). On average, equities research analysts forecast that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current fiscal year.
Institutional Trading of Aldeyra Therapeutics
Hedge funds have recently bought and sold shares of the stock. State Street Corp raised its position in shares of Aldeyra Therapeutics by 1.7% during the third quarter. State Street Corp now owns 973,908 shares of the biotechnology company's stock valued at $5,249,000 after buying an additional 16,188 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its stake in Aldeyra Therapeutics by 163.4% during the third quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company's stock valued at $2,571,000 after acquiring an additional 295,864 shares during the period. Barclays PLC increased its stake in Aldeyra Therapeutics by 280.1% during the third quarter. Barclays PLC now owns 65,561 shares of the biotechnology company's stock valued at $353,000 after acquiring an additional 48,313 shares during the period. Raymond James Financial Inc. acquired a new position in Aldeyra Therapeutics in the 4th quarter valued at approximately $3,628,000. Finally, SG Americas Securities LLC lifted its position in shares of Aldeyra Therapeutics by 14.4% in the 4th quarter. SG Americas Securities LLC now owns 22,365 shares of the biotechnology company's stock worth $112,000 after acquiring an additional 2,822 shares during the period. 59.71% of the stock is owned by institutional investors.
About Aldeyra Therapeutics
(
Get Free Report)
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
Featured Stories
Before you consider Aldeyra Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aldeyra Therapeutics wasn't on the list.
While Aldeyra Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
